Longitudinal tumor-informed ctDNA monitoring and clinical outcomes in advanced urothelial carcinoma treated with enfortumab vedotin ± pembrolizumab.

Journal of Clinical Oncology 2026

View at publisher
Authors: Adanma Ayanambakkam, Kevin R. Reyes, Ryan Zhu, Cameron Herberts, Punashi Dutta, Ashley Wray, Beaux Mitchell, Sahar Balkhi, Xiaolin Zhu, Carissa E. Chu, Sima P. Porten, Terence W. Friedlander
+7 more Jonathan Chou, Steven Neema Seyedin, Shruti Sharma, Meenakshi Malhotra, Minetta C. Liu, Adam ElNaggar, Vadim S. Koshkin
DOI: 10.1200/jco.2026.44.16_suppl.4569
Cited by: 1

Abstract

4569 Background: Enfortumab vedotin plus pembrolizumab (EV±P) is standard-of-care for patients (pts) with locally advanced/metastatic urothelial carcinoma (la/mUC), although not all pts experience durable benefit. Tumor-informed circulating tumor DNA (ctDNA) assays enable a personalized, real-time assessment of disease kinetics, and early ctDNA dynamics (24wk: HR=3.8, CI: 1.2-12.3; p=0.03). Conclusions: Longitudinal ctDNA dynamics are strongly prognostic in pts with la/mUC treated with EV±P, even when assessed beyond 12 weeks from treatment start. Sustained ctDNA negativity further identifies pts with durable clinical benefit. These findings support ctDNA as a potentially complementary biomarker to standard imaging in this clinical context.

Fields of Study & Subjects

Cancer Genomics and Diagnostics Bladder and Urothelial Cancer Treatments Single-cell and spatial transcriptomics

Publication details

Journal / source
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Volume
44
Issue
16_suppl
Pages
4569–4569
Publication date
27 May 2026
Language
EN